Abstract library

282 results for "ectopic malignant insulinoma".
#1390 Ectopic Malignant Insulinoma with Multiple Liver Metastases: A Case Report
Introduction: Malignant insulinoma arising from ectopic pancreas is very rare.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Dr. Huang Ying Tan
Authors: Liu Q, Luo J, Li C, Zhu Z H, ...
#1257 A Clinicopathological Study of Malignant Insulinoma in a Contemporary Series
Introduction: Malignant insulinoma is traditionally considered extremely rare and its natural history variable.
Conference: 13th Annual ENETS conference (2016)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Dr. Run Yu
Authors: Yu R, Nissen N N, Hendifar A, Fan X, ...
#2124 A Case Report of a Malignant Insulinoma
Introduction: Despite rare (1-2% of pancreatic tumors/PT), insulinomas are the most common functional pNET. The diagnosis is established by demonstrating inappropriately high serum insulin levels during a spontaneous or induced episode of hypoglycemia.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Theodoros Tegos
Keywords: malignant, insulinoma
#2249 Pasireotide as a Possible Tool for the Control of Refractory Hyperinsulinemic Hypoglycemia from Malignant Insulinoma
Introduction: The control of hypoglycemic hyperinsulinemic syndrome from malignant insulinoma is challenging because it is often refractory to diazoxide and somatostatin analogues (SA). Everolimus can have side effects that can limit its use. Pasireotide, a multi-receptor-targeted SA with a high binding affinity to SSTR1 and SSTR5, exhibits a strong inhibitory effect of insulin secretion.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: MD Maria Vittoria Davì
#431 Everolimus Controlled Resistant Hypoglycemia in Malignant Insulinoma
Introduction: A pancreatic neuroendocrine carcinoma with liver metastases was diagnosed on July 2006 in a 65-year-old man. He was treated with octreotide LAR 30 mg for three years. At liver progression he was enrolled in a multicenter Italian trial titled “XELBEVOCT” with Bevacizumab + Metronomic Capecitabine + Octreotide LAR 30 mg. After seven months, the patient exhibited severe hypoglycemic syndrome with HGT serum levels<30 mg/dl, insulin 150 microUI/ml, and C-peptide at upper normal limits. Endocrinologist prescribed prednisone, diazoxide and recombinant glucagon for hypoglicemic crisis, with little benefit. In March 2010, the patient was given radio-labelled Lu-177-OCTREOTATE treatment. After three cycles, hypoglicemic symptoms were still uncontrolled. CT scan showed stable disease.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Anna Ferrero
Authors: Ferrero A, Bellini E, Brizzi M P, Pia A, ...
#270 Insulinoma: A Rare Tumor?
Introduction: Insulinoma, a pancreatic ß-cell tumor, comprises 55% of neuroendocrine tumors with an annual incidence of 3-10/million. 10% are malignant, 10% are multiple and half of them present in MEN-1.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Vasiliki Daraki
#2192 Immunohistochemical Profiles in 81 Patients with Resected Insulinomas
Introduction: Ninety percent of insulinomas are benign. However, there are no well-defined immunohistochemical criteria that can distinguish a benign from a malignant insulinoma
Conference: 15th Annual ENETS conference (2018)
Category: Pathology - grading, staging
Presenting Author: MD, PhD Mikkel Andreassen
#91 Endoscopic ultrasound of 66 insulinomas
Introduction: Ultrasound is the virtual representation of the morphology of organs and tissues. Endoscopic ultrasound can be used in detailed scanning of pancreas and preoperative topical diagnostics of insulinomas. Insulinoma requires surgical treatment in all cases. This fact allows control of preoperative diagnostic methods.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Tatiana L. Silina
#50 Clinical-morphology correlation in diagnostics and evaluating surgery results of pancreatic insulinoma and nesidiobastosis
Introduction: Organic hyperinsulinism syndrome (OHS) is revealed in 85% cases of pancreas insulinoma. Nesidioblastosis (NB) induces OHS in 15% of the cases. Surgical cure provides all symptoms of insulinoma disappearing, while cytoreductive operation results in considerable improvement of life quality. There is no intraoperative opportunity to reveal insulinoma grade, even if an urgent biopsy is performed. Thus, it is essential to determine the cause of OHS and to apply the surgical cure method during the preoperational period, thereby improving the long-term prognosis.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr. Evelina Askenderova
#264 Alterations of TIMP-3 Gene in Insulinomas and Its Significance
Introduction: Our previous study on insulinoma found allelic loss of 22q12 where suppressor gene TIMP3 located. TIMP3 can inhibit tumor invasion or metastasis, but its clinical implications in insulinoma are unknown.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr Yuan-Jia Chen
Authors: Chen Y J, Zhou C Y, Wu H Y, Liu T H, ...
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.